First published study of ogm in pediatric aml shows ogm identifies mrd markers and other novel variants that can impact case management

San diego, may 26, 2022 (globe newswire) -- bionano genomics, inc. (nasdaq: bngo), pioneer of optical genome mapping (ogm) solutions on the saphyr® system and provider of nxclinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced the publication of the first peer-reviewed research study using optical genome mapping (ogm) to analyze genetic aberrations found in pediatric patients with acute myeloid leukemia (aml). this research demonstrates the use of ogm to identify minimal residual disease (mrd) markers and other novel variants that can impact therapeutic treatment and case management for pediatric aml patients. mrd markers can be followed over the course of treatment and used to determine whether treatment is working or whether the patient has relapsed.
BNGO Ratings Summary
BNGO Quant Ranking